0.7648  0.015 (1.96%)		05-13 13:12
Open: 0.75 High: 0.77 Volume: 217,137		Pre. Close: 0.7501 Low: 0.75 Market Cap: 18(M)

Short term
Mid term
Targets	6-month :	1.18	1-year :	1.37
Resists	First :	1.01	Second :	1.17
Pivot price	0.86
Supports	First :	0.75	Second :	0.62
MAs	MA(5) :	0.81	MA(20) :	0.91
	MA(100) :	0.74	MA(250) :	0.89
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	4.7	D(3) :	3.5
RSI	RSI(14): 32.6
52-week	High :	1.79	Low :	0.47

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ LGVN ] has closed above bottom band by 7.6%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.86 - 0.87	0.87 - 0.87
Low:	0.74 - 0.74	0.74 - 0.75
Close:	0.74 - 0.75	0.75 - 0.76

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Mon, 11 May 2026
LGVN SEC Filings - Longeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mon, 11 May 2026
Stem cell trial for children with rare heart defect passes final safety review - Stock Titan

Sun, 10 May 2026
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN

Fri, 08 May 2026
FDA shifts stance on Longeveron (LGVN) ELPIS II HLHS trial but keeps future path open - Stock Titan

Tue, 05 May 2026
Longeveron plans May 13 business update after market close - Stock Titan

Sun, 19 Apr 2026
[EFFECT] Longeveron Inc. SEC Filing - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	28 (M)
Held by Insiders	1.982e+007 (%)
Held by Institutions	5.6 (%)
Shares Short	4,550 (K)
Shares Short P.Month	0 (K)

EPS	-2.206e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	479.1 %
Return on Equity (ttm)	-81.3 %
Qtrly Rev. Growth	1.2e+006 %
Gross Profit (p.s.)	-141.08
Sales Per Share	-588.4
EBITDA (p.s.)	2.86786e+006
Qtrly Earnings Growth	-1.3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-19 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	-0.59

Dividend	0
Forward Dividend	2.9e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.